Corporate$NRXP8:30 AM ETdeveloping · v2

NRx Pharmaceuticals completes process validation, two-year stability for preservative-free ketamine

By BORSA NewsroomPublished Oct 19, 2026, 8:30 AM EDTUpdated Oct 19, 2026, 8:33 AM EDT

NRx Pharmaceuticals (NRXP) completed process validation and two-year stability data for preservative-free ketamine. Three commercial lots manufactured. Drug supply on hand pending FDA ANDA decision by November 10 GDUFA goal date.

Sentimentbullish 70

Bullish · 70 of 100

Impact60

medium · sector-wide

Confidence90%

high confidence · 2 wires

Eventdeveloping

v2 · alerted to followers

WHAT WE KNOW

Three commercial lots manufactured